Research

C Udovicich, D Murphy, M Hofman, M Perera, B Tran, A Azad, N Lawrentschuk, C Sarat, M Shaw, R Eapen, D Moon, S Siva
Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerised Tomography in the management of oligometastatic Renal Cell Carcinoma
European Urology Open Science. 2022, In Press

This study assesses the impact of prostate-specific membrane antigen (PSMA) PET/CT imaging in managing oligometastatic renal cell carcinoma (RCC).

Among 61 patients, 48% experienced a high-impact management change due to PSMA PET/CT results. The detection rate for PSMA-positive disease was 84%.

PSMA PET/CT proved beneficial in detecting additional metastases compared to conventional CT, influencing treatment decisions.

These findings support the potential of PSMA PET/CT as a complementary imaging modality in RCC management, though prospective studies are needed to further validate its clinical utility.

Read the full article

Dr. Marlon Perera

Dr. Marlon Perera is an Australian-trained, award-winning urology surgeon who specialises in robotic surgery and uro-oncology. Dr. Perera has worldwide experience, having completed a PhD (Urology) and a prized-accredited ‘Society of Urologic Oncology’ (SUO) fellowship at one of the world’s best and most prestigious cancer centres – Memorial Sloan Kettering Cancer Center in New York City. He provides comprehensive care in the treatment of prostate cancer, kidney masses and cancers, bladder cancer, kidney stones, and voiding dysfunction.